Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Insulin therapy is frequently needed to achieve adequate glycaemic control in type 2
diabetes. Although insulin is an effective treatment modality, this is often at the expense
of significant weight gain. Weight gain is obviously undesirable in an already overweight
population, but may also deter further optimization of insulin therapy. Large
inter-individual differences exist in the level of weight gain after initiation of insulin
therapy, but no clear predictive factors have prospectively been identified thus far.
Liraglutide (Victoza®), a human glucagon-like peptide-1 (GLP-1) analogue, improves glycaemic
control and reduces weight. We hypothesize that in patients who show (excessive) weight gain
after introducing insulin therapy, adding liraglutide is effective in reversing body weight
while preserving glycaemic control.